Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Merck & Company (MRK)
NYSE:MRK
Holding MRK?
Track your performance easily
MRK Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$94.48 - $134.63
Previous Close$99.86
Volume14.03M
Average Volume (3M)9.81M
Market Cap
$252.61B
Enterprise Value$276.21B
Total Cash (Recent Filing)$14.59B
Total Debt (Recent Filing)$38.13B
Price to Earnings (P/E)20.9
Beta0.20
Next Earnings
Feb 04, 2025EPS Estimate
$1.84Next Dividend Ex-Date
Dec 16, 2024Dividend Yield3.16%
Share Statistics
EPS (TTM)4.77
Shares Outstanding2,529,635,645
10 Day Avg. Volume11,173,005
30 Day Avg. Volume9,812,705
Standard Deviation0.06
R-Squared0.11
Alpha0.00250
Financial Highlights & Ratios
Price to Book (P/B)5.54
Price to Sales (P/S)3.87
Price to Cash Flow (P/CF)6.60
P/FCF Ratio7.20
Enterprise Value/Market CapN/A
Enterprise Value/Revenue4.37
Enterprise Value/Gross Profit6.28
Enterprise Value/Ebitda14.61
Forecast
1Y Price Target
$133.56Price Target Upside34.66% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering21
Merck & Company News
Bulls Say, Bears Say
Bulls Say
Financial PerformanceKeytruda continued its usual dominance, beating consensus estimates by +1% and contributing to an overall Oncology portfolio beat.
Growth OpportunitiesMRK is optimistic regarding Gardasil China approval for male vaccination, which could present a future growth opportunity.
Product InnovationSubcutaneous Keytruda has the potential to improve the efficiency of medical practices and free up infusion centers.
Bears Say
Clinical Trials And ApprovalsCompetitor Summit Therapeutics presented detailed data from their HARMONi-2 Phase 3 trial in PD-L1 positive NSCLC showing a statistically significant median PFS benefit compared to MRK's Keytruda.
Financial PerformanceGardasil remains a concern with revenues -10% vs. consensus, likely continued to be impacted by problems in China.
Product CompetitionA local competitor is poised to launch their own 9-valent option in China next year, potentially impacting Merck's market share.
---
Ownership Overview
0.04% Insiders
21.36% Mutual Funds
15.50% Other Institutional Investors
42.26% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Legal & RegulatoryLitigation, compliance, new legislation, and taxation risks
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
MRK FAQ
What was Merck & Company’s price range in the past 12 months?
Merck & Company lowest stock price was $94.48 and its highest was $134.63 in the past 12 months.
What is Merck & Company’s market cap?
Currently, no data Available
When is Merck & Company’s upcoming earnings report date?
Merck & Company’s upcoming earnings report date is Feb 04, 2025 which is in 72 days.
How were Merck & Company’s earnings last quarter?
Merck & Company released its earnings results on Oct 31, 2024. The company reported $1.57 earnings per share for the quarter, beating the consensus estimate of $1.484 by $0.086.
Is Merck & Company overvalued?
According to Wall Street analysts Merck & Company’s price is currently Undervalued.
Does Merck & Company pay dividends?
Merck & Company pays a Quarterly dividend of $0.81 which represents an annual dividend yield of 3.16%. See more information on Merck & Company dividends here
What is Merck & Company’s EPS estimate?
Merck & Company’s EPS estimate is $1.84.
How many shares outstanding does Merck & Company have?
Merck & Company has 2,529,635,700 shares outstanding.
What happened to Merck & Company’s price movement after its last earnings report?
Merck & Company reported an EPS of $1.57 in its last earnings report, beating expectations of $1.484. Following the earnings report the stock price went down -2.394%.
Which hedge fund is a major shareholder of Merck & Company?
Among the largest hedge funds holding Merck & Company’s share is Fisher Asset Management LLC. It holds Merck & Company’s shares valued at 2B.
---
Merck & Company Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$133.56 (34.66% Upside)
$133.56 (34.66% Upside)
Blogger Sentiment
Bullish
MRK Sentiment 87%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Increased
By 32.6K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Positive
Last 7 Days ▼ 0.7%
Last 30 Days ▲ 3.9%
Last 30 Days ▲ 3.9%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
0.29%
12-Months-Change
Fundamentals
Return on Equity
28.33%
Trailing 12-Months
Asset Growth
10.12%
Trailing 12-Months
Company Description
Merck & Company
Merck & Co., Inc. develops pharmaceutical and vaccine products. It also offers healthcare solutions and vaccines addressing animal health. The company was founded in 1891 and is headquartered in Kenilworth, NJ.
---
MRK Company Deck
---
MRK Earnings Call
Q3 2024
0:00 / 0:00
---
MRK Sales Breakdown
45.91% Oncology
22.09% Vaccines
5.64% Hospital Acute Care
5.60% Diabetes
20.75% Other
---
MRK Stock 12 Month Forecast
Average Price Target
$133.56
▲(34.66% Upside)
Technical Analysis
Best Analysts Covering MRK
1 Year
1 Year Success Rate
25/41 ratings generated profit
1 Year Average Return
+9.19%
assigned a buy rating 23 days ago
Copying Daina Graybosch's trades and holding each position for 1 Year would result in 60.98% of your transactions generating a profit, with an average return of +9.19% per trade.
---